Plasma levels of dehydrolithocholic acid (DHLCA) were significantly lower in patients with (DKD) and macroalbuminuria compared to those with type 2 diabetes mellitus.
DHLCA levels showed a negative correlation with urine albumin and urine albumin-to-creatinine ratio.
In a mouse model of DKD, DHLCA administration significantly reduced urine albumin-to-creatinine ratio and fasting blood glucose levels.
DHLCA treatment improved liver function and reduced markers of kidney injury in DKD mice.
The treatment restored the expression of certain receptors () in kidney tissue.
Metagenomic analysis indicated changes in gut microbiota composition following DHLCA treatment.
Simplified
PURPOSE: (DKD) is a major contributor to chronic kidney disease worldwide. (BAs) are increasingly recognized as key regulators of glucose metabolism and kidney function. This study aimed to investigate the role of BA metabolism in the progression of DKD.
METHODS: Plasma BA profiles were measured in healthy controls (HC), patients with type 2 diabetes mellitus (T2DM), and patients with DKD using ultra-high-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). After identifying potential BA biomarkers in the clinical cohort, in vivo validation was conducted using dehydrolithocholic acid (DHLCA) intervention in DKD mouse model. Kidney injury markers, as well as the expression of Takeda G protein-coupled receptor 5 (TGR5) and farnesoid X receptor (FXR), were evaluated. In addition, gut microbiota (GM) composition was analyzed via metagenomic sequencing following DHLCA treatment.
RESULTS: The plasma DHLCA levels were significantly lower in DKD with macroalbuminuria group compared to T2DM group and DKD with microalbuminuria group (< 0.01). Partial Spearman correlation analysis adjusted for age and diabetes duration showed that DHLCA levels were negatively correlated with urine albumin (= -0.347; 95% CI, -0.531 to -0.135; q = 0.008) and urine albumin-to-creatinine ratio (UACR) (= -0.332; 95% CI, -0.499 to -0.155; q = 0.010). In vivo, DHLCA administration significantly reduced UACR and fasting blood glucose (FBG) levels (< 0.01), and improved liver function (ALT,< 0.05) in DKD mice. DHLCA treatment attenuated renal tubular injury, restored expression in kidney tissue, and decreased levels of kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL). Metagenomic analysis revealed an enrichment offollowing DHLCA treatment. P ρ ρ P P Lachnospiraceae bacterium
CONCLUSION: DHLCA may represent a promising therapeutic candidate for DKD by targeting the TGR5/FXR signaling pathway and GM remodeling. Its metabolic and kidney benefits, along with an improved hepatic profile and absence of hepatotoxicity, support further translational investigation.
Key numbers
< 0.01
Decrease in DHLCA Levels
DHLCA levels in with macroalbuminuria vs. T2DM and microalbuminuria groups.
< 0.01
Reduction in UACR
UACR levels in mice treated with DHLCA.
< 0.05
Improvement in ALT Levels
Comparison of ALT levels in mice treated with DHLCA vs. untreated.
Full Text
We can’t show the full text here under this license.
All authors declare that there exists no potential competing interest. No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article. Hua Zhou, Xiaodie Mu and Huiyue Hu contributed equally to this work as Co-first authors. Jingting Jiang and Min Yang contributed equally to this work as Co-corresponding authors.
